327 results on '"Covington, Maryanne"'
Search Results
2. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment
3. Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2
4. Abstract 5162: Discovery of INCB098377: a potent inhibitor of phosphoinositide 3-kinase gamma (PI3Kγ)
5. Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
6. Supplementary Table from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
7. Supplementary Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
8. Supplementary Figure from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
9. Supplemental Data from The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies
10. Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach
11. Potent and Selective Biaryl Amide Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)
12. Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors
13. Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3
14. Discovery of 5,7-Dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors
15. Discovery of a novel 2-spiroproline steroid mimetic scaffold for the potent inhibition of 11β-HSD1
16. Discovery of 1′-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3′-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11β-HSD1 using a scaffold-hopping approach
17. Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2
18. Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
19. Discovery of a Novel 2-Spiro-Proline Steroid Mimetic Scaffold for the Potent Inhibition of 11β-Hsd1
20. Potent and Selective Biaryl Amide Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).
21. Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors.
22. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
23. 232 INCB090244, a potent small molecule that inhibits the PD-L1/PD-1 axis and functions similarly to PD-L1 antibodies
24. Mechanism of Selective Inhibition of the Inducible Isoform of Prostaglandin G/H Synthase
25. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
26. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
27. Abstract LB157: Discovery and characterization of INCB106385: a novel A2A/A2B adenosine receptor antagonist, as a cancer immunotherapy
28. Comparison of the Enzymatic and Cellular Profiles of Clinical JAK2 Inhibitors for the Treatment of Myelofibrosis
29. ALK2 and JAK2 Inhibition for Improved Treatment of Anemia in Myelofibrosis Patients: Preclinical Profile of an ALK2 Inhibitor Zilurgisertib in Combination with Ruxolitinib
30. A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity
31. INCB38579, a novel and potent histamine H4 receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functions
32. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases
33. Abstract 2648: L-arginine regulates chemotherapy sensitivity via ER stress and autophagic pathways in arginine prototrophic cancer cells
34. Abstract 4513: The role of HPK1 in the regulation of T cell function and anti-tumor immune activity
35. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy
36. Discovery of potent and selective PI3Kγ inhibitors via elaboration of a designed fragment and identification of key metabolites
37. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
38. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
39. INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)
40. Abstract 4480: Preclinical characterization of potent and selective oral PD-L1 small-molecule antagonists
41. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies
42. Abstract 3759: Characterization of INCB081776, a potent and selective dual AXL/MER kinase inhibitor
43. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies
44. P 1, P 2′-Linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors
45. Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-α production
46. Terphenyl cyclooxygenase-2 (COX-2) inhibitors: Optimization of the central ring and o-biphenyl analogs
47. INCB040093 Is a Novel PI3KδInhibitor for the Treatment of B Cell Lymphoid Malignancies
48. Abstract 5071: Preclinical characterization of the potent and selective BET inhibitor INCB057643 in models of hematologic malignancies
49. Abstract 2100: Selective inhibition of FGFR4 by INCB062079 is efficacious in models of FGF19- and FGFR4-dependent cancers
50. Abstract 4696: The LSD1 inhibitor INCB059872 is synergistic with ATRA in models of non-APL acute myelogenous leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.